Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jasper Therapeutics, Inc. (JSPR : NSDQ)

• Company Description    Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif. Number of Employees: 64

• Price / Volume Information    Yesterday's Closing Price: $2.43 Daily Weekly Monthly 20 Day Moving Average: 148,955 shares Shares Outstanding: 16.25 (millions) Market Capitalization: $39.49 (millions) Beta: 2.77 52 Week High: $26.05 52 Week Low: $2.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.80% -21.21% 12 Week -53.80% -58.04% Year To Date -88.63% -89.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 BRIDGE PKWY SUITE #102 - REDWOOD CITY,CA 94065 USA ph: 650-549-1400 fax: - ir@jaspertherapeutics.com https://jaspertherapeutics.com

• General Corporate Information    Officers Ronald Martell - President; Chief Executive Officer Thomas G. Wiggans - Chairperson of the Board Herb Cross - Chief Financial Officer Vishal Kapoor - Director Kurt von Emster - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 471871202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 16.25 Most Recent Split Date: 1.00 (0.10:1) Beta: 2.77 Market Capitalization: $39.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.01 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.68 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -79.38% vs. Previous Quarter: -23.40% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -172.28 03/31/25 - -109.45 12/31/24 - -79.43 ROA 06/30/25 - -128.34 03/31/25 - -89.82 12/31/24 - -68.00 Current Ratio 06/30/25 - 2.10 03/31/25 - 4.31 12/31/24 - 4.98 Quick Ratio 06/30/25 - 2.10 03/31/25 - 4.31 12/31/24 - 4.98 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 1.45 03/31/25 - 2.81 12/31/24 - 4.11 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©